CD BioGlyco Provides Integrated Solutions for Glycoprotein Vaccine Design
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines.
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are critical in viral attachment and cell fusion, and investigation of these proteins may provide valuable insights into their potential use in vaccines and antiviral strategies. The immunogenicity of E1 and E2 has led to various ongoing attempts to develop one or both envelope glycoproteins into vaccines.
For the development, expression, or synthesis of glycoprotein vaccine candidates, CD BioGlyco has created a variety of systematic and cutting-edge solutions.
In order to express immunogenic glycoproteins, CD BioGlyco has developed glyco-engineered yeast systems, plant systems, insect cell systems, mammalian cell systems, and viral vector systems. Related studies on the structural resemblances between them and the natural antigen and how they affect the immune system may be conducted to generate ideas for a novel rabies genetic engineering vaccine.
CD BioGlyco also has chemical and chemoenzymatic platforms to carry out site-specific glycosylation and make sure the homogeneous, highly pure glycoprotein vaccine candidates obtained are operated simply and effectively under benign conditions.
Additionally, the company offers specialized glycoprotein remodeling services that can be used to generate desired glycoproteins using natural chemical linkage (NCL), expressed protein ligation (EPL), and chemoenzymatic techniques.
Recombinant Glycoprotein Vaccine Development
In order to assist customers in designing and producing recombinant glycoprotein vaccines with good tolerability, safety, and immunogenicity, CD BioGlcyo has built a specialized platform and a number of cutting-edge solutions.
Synthetically Defined Glycoprotein Vaccine Development
With the aid of cutting-edge oligosaccharide synthesis and protein site-specific functionalization techniques, CD BioGlyco offers services for the design and production of synthetically specified glycoprotein vaccines.
“Our organization has cutting-edge technology platforms that are distinctive and cutting edge in vaccine development. We can help you in the process of developing a vaccination thanks to our excellent researchers and cutting-edge equipment.” Commented Anna, one of the representative speakers from CD BioGlyco.
To know more detailed information about the Glycoprotein-based Vaccine Development provided by CD BioGlyco, please visit https://www.bioglyco.com/glycoprotein-based-vaccine-development.html.